Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alaina Vincent

Physician Assistant Media, PA Physician Assistant

NPI 1689967747 CMS profile 10777449

200 E State St Ste 205, Media, PA 19063

Open in the dashboard

General payments

$6,979

186 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alaina Vincent of Media, PA is reported in the CMS Open Payments database as having received $6,979 across 186 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,125 75
2024 General $1,312 43
2023 General $586 31
2022 General $643 24
2021 General $313 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alaina Vincent
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Alaina Vincent were reported at $4,125. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Alaina Vincent Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $313 $132 $37–$438 $132
2022 $643 $155 $48–$522 $149
2023 $586 $167 $52–$557 $160
2024 $1,312 $178 $55–$600 $164
2025 $4,125 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $2,244 29 payments
  2. Janssen Biotech, Inc. $1,820 29 payments
  3. Astellas Pharma US Inc $505 17 payments
  4. Pfizer Inc. $360 18 payments
  5. Teleflex LLC $271 12 payments
  6. Janssen Scientific Affairs, LLC $265 2 payments
  7. Merck Sharp & Dohme Corporation $251 13 payments
  8. AstraZeneca Pharmaceuticals LP $201 12 payments
  9. Tolmar, Inc. $190 10 payments
  10. Novartis Pharmaceuticals Corporation $149 7 payments
  11. Other $725 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,516 180 payments
  2. Consulting Fee $1,904 2 payments
  3. Travel and Lodging $479 3 payments
  4. Education $79 1 payment
Products named General payments · program years 2021–2025
  1. ERLEADA $2,084 31 payments
  2. XTANDI $785 34 payments
  3. Nubeqa $730 21 payments
  4. Xofigo $356 15 payments
  5. ORGOVYX $337 17 payments
  6. TALZENNA $316 16 payments
  7. KEYTRUDA $251 13 payments
  8. LYNPARZA Oncology $201 12 payments
  9. LYNPARZA Oncology $161 9 payments
  10. UroLift System $160 5 payments
  11. Other $1,814 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$71,628

Of which drugs: $60,200

Medicare patients

93

Average age 79

Services billed

2,858

14 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 47%
Atrial fibrillation 45%
Ischemic heart disease 44%
Arthritis 44%
Diabetes 40%
Chronic kidney disease 39%
Depression 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 13 81 $11,445

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTANDI
  • Astellas Pharma US Inc $206
  • PFIZER INC. $38
$244 — —
ERLEADA
  • Janssen Scientific Affairs, LLC $143
  • Janssen Biotech, Inc. $82
$226 — —
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $192
$192 — —
AKEEGA
  • Janssen Biotech, Inc. $59
$59 — —
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record